Seminars in Oncology
Volume 36, Issue 2 , Pages 170-180 , April 2009

Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group

  • Krishnansu S. Tewari

      Affiliations

    • Corresponding Author InformationAddress correspondence to Krishnansu S. Tewari, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine–Medical Center, 101 The City Dr S, Building 56, Room 275, Orange, CA 92868
    • ,
  • Bradley J. Monk

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Monk BJ, Tewari KS, Kow WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;27:2952–2965
  3. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419–434
  4. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. 2008;Abstract #45. Presented at: 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL
  5. Sill MW, Monk BJ, McMeekin DS, Cohn D, Ramondetta L, Boardman , et al. A randomized phase III trial of four cisplatin (cis) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. 2008;Late-breaking Abstract. Presented at: Annual Meeting of the American Society of Clinical Oncology; Chicago, IL
  6. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17:2676–2680
  7. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–3119
  8. Long HJ, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol. 1995;57:235–239
  9. Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85:89–94
  10. Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–4633
  11. Monk BJ, Huang HQ, Cella D, Long HJ. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4617–4625
  12. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996;88:734–741
  13. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165–171
  14. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:1832–1837
  15. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792–795
  16. Moore DH, Tian C, Monk BJ, Long HJ, Omura G. Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: a multivariate analysis of three Gynecologic Oncology Group trials (Abstract no. 5534). J Clin Oncol ASCO Annual Meeting Proceedings Part 1. 2007;25:18S
  17. JCOG0505. Trial of cisplatin plus paclitaxel versus carboplatin plus paclitaxel regimens for stage IVB, perisistent, or recurrent cervical cancer. (R. Kitagawa and T. Kamura study chairs). Available at: www.clinicaltrials.gov.
  18. Symonds R, Davidson S, Chan S, Reed N, McMahon T, Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer (Abstract no. 5548). J Clin Oncol ASCO Annual Meeting Proceedings Part 1. 2007;25:18S
  19. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001;48:188–196
  20. Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92:635–638
  21. West W, Birch R, Schnell F, Hainsworth J, Tongol J, Campos L. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. Oncology. 2003;8:76–82
  22. Stathopoulos GP, Rigatos SK, Christodoulou C, Malamos NA, Deliyiannis F, Stathopoulos JG, et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol. 2004;54:259–264
  23. Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou C, Stathopoulos J, et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol. 2007;60:123–126
  24. Homesley HD, Benigno B, Williams J, Vaccarello L. A phase I study of weekly topotecan and paclitaxel in previously treated ovarian carcinoma patients. Gynecol Oncol. 2002;87:171–177
  25. A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan to those of cisplatin and topotecan for treatment of patients with recurrent or persistent cervical cancer. AGO protocol IFG-01-0106 (F. Thiel study chair). www.ago-online.org.
  26. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med. 1998;338:991–992
  27. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997;3:1501–1505
  28. Cooper RA, Wilks DP, Logue JP, Davidson SE, Hunter RD, Roberts SA, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res. 1998;4:2795-00
  29. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–844
  30. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58:2594–2600
  31. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. Biodrugs. 2006;20:193–195
  32. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  33. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (EGOC) study E3200 (Abstract no. 169a). J Clin Oncol ASCO Annual Meetings Proceedings. 2007;23:16S
  34. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  35. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  36. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  37. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endoetherlial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  38. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JL. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165–5171
  39. GOG 218. A phase III trial of carboplatin and paclitaxel polus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC #704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, stage III or IV, epithelial ovarian or primary peritoneal cancer. (R.A. Burger study chair). www.gog.org.
  40. ICON-7. A randomized, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. (T. Perren study chair). www.icon7trial.org.
  41. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489–493
  42. Hung C-F, Ma B, Monie A, Tsen S-W, Wu T-C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8:421–439
  43. Hung C-F, Wu TC, Monie A, Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev. 2008;222:43–69
  44. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005;10:528–538
  45. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1532–1537
  46. Ressing ME, van Driel WJ, Brandr RM, Kenter GG, de Jong JH, Bauknecht T, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000;23:255–266
  47. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, et al. Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999;35:946–952
  48. Steller MA, Gurski KJ, Mutakami M, Daniel RW, Shah KV, Celis E, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lapidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998;4:2103–2109
  49. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metasatic cervical cancer. N Engl J Med. 2002;346:1752–1753
  50. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, et al. HPV 16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006;100:469–478

PII: S0093-7754(08)00265-0

doi: 10.1053/j.seminoncol.2008.12.008

Seminars in Oncology
Volume 36, Issue 2 , Pages 170-180 , April 2009

Article Tools

* Image Usage & Resolution